Patients with mesothelioma, a cancer of the lung lining caused by exposure to asbestos, may someday benefit from a new 3D PET measure that helps accurately and quickly measure response to chemotherapy, according to Australian researchers.
Patients with mesothelioma, a cancer of the lung lining caused by exposure to asbestos, may someday benefit from a new 3D PET measure that helps accurately and quickly measure response to chemotherapy, according to Australian researchers.
Investigators at Sir Charles Gairdner Hospital's PET Center in Western Australia and other area centers developed software to assess total glycolytic volume (TGV), a 3D measure that reflects tumor volume and metabolic activity on FDG-PET scans. They compared TGV and maximum standardized uptake values (SUVmax) for PET and CT-based measures on 23 patients with mesothelioma set to undergo cisplatin and gemcitabine treatment.
Results showed that TGV can measure tumor response after just one round of chemotherapy. TGV also proved more accurate predicting survival than did both SUVmax and CT (JNM 2007:48:1449-1458).
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.